These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 17264849

  • 1. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U.
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A, OBD-202 Study Group.
    Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
    [Abstract] [Full Text] [Related]

  • 3. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, OBES-002 Study Group.
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.
    Lancet; 2011 Apr 16; 377(9774):1341-52. PubMed ID: 21481449
    [Abstract] [Full Text] [Related]

  • 6. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.
    Obes Res; 2003 Jun 16; 11(6):722-33. PubMed ID: 12805393
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.
    Int J Obes (Lond); 2007 Jan 16; 31(1):138-46. PubMed ID: 16703004
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug 16; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 10. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese.
    Syvertsen C, Halse J, Høivik HO, Gaullier JM, Nurminiemi M, Kristiansen K, Einerhand A, O'Shea M, Gudmundsen O.
    Int J Obes (Lond); 2007 Jul 16; 31(7):1148-54. PubMed ID: 17031391
    [Abstract] [Full Text] [Related]

  • 11. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr 16; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 12. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes.
    Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S.
    Diabetes Care; 2018 Apr 16; 41(4):807-814. PubMed ID: 29439147
    [Abstract] [Full Text] [Related]

  • 13. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S.
    Metabolism; 2001 Dec 16; 50(12):1457-61. PubMed ID: 11735093
    [Abstract] [Full Text] [Related]

  • 14. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects.
    Belza A, Frandsen E, Kondrup J.
    Int J Obes (Lond); 2007 Jan 16; 31(1):121-30. PubMed ID: 16652130
    [Abstract] [Full Text] [Related]

  • 15. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Kuo CS, Pei D, Yao CY, Hsieh MC, Kuo SW.
    Int J Clin Pract; 2006 Aug 16; 60(8):906-10. PubMed ID: 16893433
    [Abstract] [Full Text] [Related]

  • 16. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
    Nam SY, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB.
    Int J Obes Relat Metab Disord; 2001 Aug 16; 25(8):1101-7. PubMed ID: 11477493
    [Abstract] [Full Text] [Related]

  • 17. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB.
    Clin Endocrinol (Oxf); 2006 Apr 16; 64(4):444-9. PubMed ID: 16584518
    [Abstract] [Full Text] [Related]

  • 18. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B.
    Diabetes Care; 2014 Dec 16; 37(12):3309-16. PubMed ID: 25249652
    [Abstract] [Full Text] [Related]

  • 19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 16; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 20. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, Després JP.
    Eur J Clin Pharmacol; 2007 Feb 16; 63(2):123-34. PubMed ID: 17200837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.